FDA Clears Seven Agrylin Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
The ANDAs were pending while the agency resolved a citizen petition from Shire questioning FDA’s method for establishing bioequivalence of the antithrombotic agent.